AR050102A1 - Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida - Google Patents

Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida

Info

Publication number
AR050102A1
AR050102A1 ARP050103260A ARP050103260A AR050102A1 AR 050102 A1 AR050102 A1 AR 050102A1 AR P050103260 A ARP050103260 A AR P050103260A AR P050103260 A ARP050103260 A AR P050103260A AR 050102 A1 AR050102 A1 AR 050102A1
Authority
AR
Argentina
Prior art keywords
polypeptide
composition
gag
previous
immunogenic
Prior art date
Application number
ARP050103260A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR050102A1 publication Critical patent/AR050102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a nuevas fusiones de polipéptidos y polinucleotidos de VIH de Gal, Pol y Nef que son utiles en composiciones inmunogénicas y vacunas. La invencion se refiere en particular a un polipéptido que comprende Nef o un fragmento inmunogénico de la misma, y p17 Gag y/o p24 Gag o fragmentos inmunogénicos de las mismas, en el que cuando ambas p17 y p24 Gag están presentes hay al menos un antígeno de VIH o fragmento inmunogénico entre ellos. El polipéptido también puede comprender Pol o RT o un fragmento inmunogénico de las mismas. Reivindicacion 8: Un procedimiento para la purificacion de un polipéptido de acuerdo con algunas de las reivindicaciones 1 a 7, tal procedimiento comprende: i) proporcionar una composicion que comprende el polipéptido no purificado; ii) someter la composicion a al menos dos etapas cromatográficas; iii) de forma opcionan carboxiamidacion del polipéptido; v) llevar a cabo una etapa de intercambio en tampon para proporcionar la proteína en un tampon adecuado para una formulacion farmacéutica. Reivindicacion 27: Una composicion farmacéutica que comprende un polipéptido o polinucleotido o composicion de polipéptidos o polinucleotidos de acuerdo con cualquier reivindicacion previa o un polipéptido purificado de acuerdo con cualquier reivindicacion previa, o un polipéptido purificado de acuerdo con cualquier reivindicacion previa, junto con un vehículo o adyuvante farmacéuticamente aceptable.
ARP050103260A 2004-08-05 2005-08-04 Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida AR050102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine

Publications (1)

Publication Number Publication Date
AR050102A1 true AR050102A1 (es) 2006-09-27

Family

ID=32982606

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103260A AR050102A1 (es) 2004-08-05 2005-08-04 Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
ARP110100503A AR080216A2 (es) 2004-08-05 2011-02-18 Composiciones farmaceuticas que contienen una proteina de fusion de vih

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110100503A AR080216A2 (es) 2004-08-05 2011-02-18 Composiciones farmaceuticas que contienen una proteina de fusion de vih

Country Status (32)

Country Link
US (2) US7612173B2 (es)
EP (3) EP1773999B1 (es)
JP (3) JP2008507987A (es)
KR (1) KR101501495B1 (es)
CN (2) CN102633866B (es)
AR (2) AR050102A1 (es)
AT (1) ATE443769T1 (es)
AU (1) AU2005268856B2 (es)
BR (1) BRPI0514108A (es)
CA (1) CA2575898C (es)
CY (1) CY1109667T1 (es)
DE (1) DE602005016810D1 (es)
DK (1) DK1773999T3 (es)
ES (3) ES2486669T3 (es)
GB (1) GB0417494D0 (es)
HK (1) HK1108168A1 (es)
HR (1) HRP20090678T1 (es)
IL (2) IL180947A0 (es)
MA (1) MA28983B1 (es)
MX (1) MX2007001515A (es)
MY (1) MY145614A (es)
NO (1) NO20070988L (es)
NZ (1) NZ552976A (es)
PE (1) PE20060577A1 (es)
PL (1) PL1773999T3 (es)
PT (1) PT1773999E (es)
RU (1) RU2441878C2 (es)
SG (1) SG155206A1 (es)
SI (1) SI1773999T1 (es)
TW (1) TWI365191B (es)
WO (1) WO2006013106A2 (es)
ZA (1) ZA200700771B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
CN1192766C (zh) * 1998-10-23 2005-03-16 伊迪亚股份公司 开发、测试和使用用于改进的有效负载和可控制性解缔/缔合速度的大分子和复合聚集体的缔合物的方法
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
AR053275A1 (es) * 2005-05-12 2007-04-25 Glaxo Group Ltd Composicion de vacuna
US20070020238A1 (en) * 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
EP2013227A4 (en) * 2006-05-09 2010-07-28 Jackson H M Found Military Med ANTI-HIV-1 IMMUNOGENIC COMPOSITIONS
EP2520168B1 (en) 2006-07-21 2014-03-19 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
EA021391B1 (ru) * 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
CA2682045A1 (en) * 2007-03-26 2008-10-02 International Aids Vaccine Initiative Method of eliciting immune response with a modified mva viral hiv-1 vector
EP2148697B1 (en) 2007-05-24 2012-10-03 GlaxoSmithKline Biologicals S.A. Lyophilised cpg containing wt-1 composition
JP2011506565A (ja) * 2007-12-21 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CA2730742C (en) * 2008-07-16 2017-05-23 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
AP2857A (en) 2008-09-09 2014-02-28 Celebrity Biogens Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
NZ597804A (en) 2009-07-24 2013-10-25 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
AU2011231574A1 (en) * 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
AU2011252850B2 (en) 2010-05-14 2016-03-17 Baxalta GmbH OspA chimeras and use thereof in vaccines
BR112013007308A2 (pt) * 2010-09-27 2016-07-05 Glaxosmithkline Biolog Sa vacina
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
EP2978449B1 (en) * 2013-03-26 2021-09-08 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
JP2023520370A (ja) 2020-03-27 2023-05-17 スヴェンスカ ヴァクチンファブリケン プロダクション アーベー コロナウイルスの治療および予防のための組成物および方法
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
EP0717752B1 (en) * 1993-05-18 2004-11-24 Macfarlane Burnet Centre For Medical Research Limited Therapeutic compounds
BR9408071A (pt) 1993-11-17 1996-12-24 Om Lab Sa Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1104310B1 (en) 1998-08-04 2009-07-01 The Henry M. Jackson Foundation for the advancement of Military Medicine, Inc. Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
WO2001043693A2 (en) 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
CA2392877C (en) * 1999-12-23 2011-11-15 Tomas Hanke Improvements in or relating to immune responses to hiv
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1427826B1 (en) 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
WO2003080112A2 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
NZ537125A (en) * 2002-06-11 2006-08-31 Glaxosmithkline Biolog S Immunogenic compositions
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
AU2004276559A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited HIV pharmaccines
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
DK1773999T3 (da) 2010-01-18
JP2011234722A (ja) 2011-11-24
EP2130921A3 (en) 2010-03-03
CN102633866B (zh) 2015-04-15
EP2130921A2 (en) 2009-12-09
NZ552976A (en) 2010-01-29
PT1773999E (pt) 2009-12-16
AU2005268856A1 (en) 2006-02-09
KR20070041765A (ko) 2007-04-19
IL180947A0 (en) 2007-07-04
CA2575898A1 (en) 2006-02-09
SG155206A1 (en) 2009-09-30
TWI365191B (en) 2012-06-01
KR101501495B1 (ko) 2015-03-11
JP2008507987A (ja) 2008-03-21
US20070243203A1 (en) 2007-10-18
CY1109667T1 (el) 2014-08-13
CN101035897A (zh) 2007-09-12
HRP20090678T1 (hr) 2010-01-31
BRPI0514108A (pt) 2008-05-27
IL207575A0 (en) 2011-07-31
ZA200700771B (en) 2009-04-29
EP2280073B1 (en) 2014-06-11
ES2445453T3 (es) 2014-03-03
DE602005016810D1 (de) 2009-11-05
EP2280073A3 (en) 2011-06-29
ES2486669T3 (es) 2014-08-19
CN102633866A (zh) 2012-08-15
PL1773999T3 (pl) 2010-02-26
GB0417494D0 (en) 2004-09-08
PE20060577A1 (es) 2006-08-07
CN101035897B (zh) 2012-02-01
US20100184836A1 (en) 2010-07-22
HK1108168A1 (en) 2008-05-02
JP5629647B2 (ja) 2014-11-26
EP2130921B1 (en) 2013-11-20
RU2441878C2 (ru) 2012-02-10
RU2007104088A (ru) 2008-09-10
EP2280073A2 (en) 2011-02-02
NO20070988L (no) 2007-05-04
ATE443769T1 (de) 2009-10-15
SI1773999T1 (sl) 2010-01-29
MA28983B1 (fr) 2007-11-01
MY145614A (en) 2012-03-15
JP2014239687A (ja) 2014-12-25
US7612173B2 (en) 2009-11-03
AR080216A2 (es) 2012-03-21
WO2006013106A3 (en) 2006-08-17
JP6007212B2 (ja) 2016-10-12
AU2005268856B2 (en) 2012-05-24
EP1773999A2 (en) 2007-04-18
ES2334044T3 (es) 2010-03-04
WO2006013106A2 (en) 2006-02-09
MX2007001515A (es) 2007-09-07
TW200621806A (en) 2006-07-01
EP1773999B1 (en) 2009-09-23
CA2575898C (en) 2015-09-29

Similar Documents

Publication Publication Date Title
AR050102A1 (es) Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
RU2007139915A (ru) Haemophilus influenzae типа в
WO2021243122A3 (en) Engineered coronavirus spike (s) protein and methods of use thereof
NO20070551L (no) Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
AR031520A1 (es) Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
AR036566A1 (es) Vacunas para vih 1
AR072302A1 (es) Pestivirus atenuados. composicion inmunogenica. metodo.
JP2008539164A5 (es)
JP2002533125A5 (es)
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
PE20090163A1 (es) CONJUGADOS DE PEPTIDOS ANTIFUSOGENICOS Y POLIPEPTIDOS DERIVADOS DE LA CABEZA GLOBULAR DEL FACTOR DEL COMPLEMENTO C1q
WO2021226026A3 (en) Vaccines against viral pathogens
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
ES2192433B1 (es) Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Legal Events

Date Code Title Description
FG Grant, registration